Concord Drugs Ltd - 538965 - Shareholding for the Period Ended March 31, 2020
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here20-05-2020
20-05-2020
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer11-05-2020
Concord Drugs Ltd - 538965 - Closure of Trading Window
Closure of Trading Window for the Quarter ended 31.03.202030-03-2020
Concord Drugs Ltd - 538965 - Un-Audited Financial Results For The Quarter Ended 31.12.2019
Un-audited Financial Results for the Quarter ended 31.12.201913-02-2020
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended 31.12.2019
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2020 ,inter alia, to consider and approve 1. Un-audited financial results for the quarter ended 31.12.2019 2. Any other business with the permission of the Chair.31-01-2020
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 201820-01-2020
Concord Drugs Ltd - 538965 - Shareholding for the Period Ended December 31, 2019
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here20-01-2020
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer20-01-2020
Concord Drugs Ltd - 538965 - Closure of Trading Window
closure of Trading window for the quarter ended 31.12.201931-12-2019
Concord Drugs Ltd - 538965 - Revised Financial Statements For The Financial Year Ended 31.03.2018
Revised Financial statements for the Financial Year ended 31.03.201811-12-2019